Form 4: ARS Pharmaceuticals Director Laura Shawver Executes Stock Options and Sells Shares

Director Laura Shawver exercised stock options and sold shares of ARS Pharmaceuticals, Inc. on April 7, 2025, according to a Form 4 filing with the SEC.

Summary

• On April 7, 2025, Laura Shawver, a director at ARS Pharmaceuticals, Inc., exercised stock options to acquire 22,509 and 27,493 shares of common stock at a price of $4.85 per share.
• Following the exercise of these options, Shawver sold 50,002 shares of common stock at a weighted average price of $12.301, with prices ranging from $12.0063 to $12.64.
• After these transactions, Shawver directly owns 210,346 shares of ARS Pharmaceuticals, Inc.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 16, 2024.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions were pre-planned under a 10b5-1 trading plan and do not necessarily reflect the director's current outlook on the company.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into a company's prospects; however, transactions under 10b5-1 plans are pre-scheduled and may not reflect current sentiment.

Stakeholder Impact

• Shareholders may react to the insider selling activity, although the pre-planned nature of the transactions mitigates the impact.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, stock options, ARS Pharmaceuticals, SPRY, insider trading, Laura Shawver, Rule 10b5-1, stock sale, director